The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.
Taking fluid management and connectivity to the next level. Never seen before.Pamper yourself in the fresh web-site www.conceptomed.com. With this gift box of selected goodies from our proprietary technology library, and as a tribute to simplicity, we wish you a Happy New Medtech Year 2019.New year greetings from the ConceptoMed team!
ConceptoMed AS is delighted to announce a new partner for the Norwegian hospital market. We have entered into a distribution agreement with Vingmed AS granting exclusive rights for marketing, sales and distribution of the LuerJack syringes in the hospital market in Norway.
ConceptoMed AS has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LuerJack Slip syringes and the first LuerJack Lock 10ml syringe.
On the 14th of February 2017, the Chinese Patent and Trademark office issued an official document granting the Chinese patent for LuerJack. ConceptoMed’s strategy to protect our intellectual property rights (IPR) remains unchanged and strong. Along with other markets already protected, such as Europe, the US, Australia and Mexico, protection in Asia is now following.
ConceptoMed AS received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first size of the Luer-Jack® syringe.
In December 2016, ConceptoMed have entered into important collaborations with suppliers of sterilization services (Sterigenics) and logistics & healthcare warehousing services (DSV Logistics) to secure the global strategy for ConceptoMed and Luer-Jack.
On Thursday 8th of December 2016, ConceptoMed was named Company of the Year 2016 among approx 190 members of Oslo Medtech, a health technology cluster dedicated to accelerate and support the development of new medtech and eHealth products, services and innovative solutions for the Norwegian and global health care market.
On the 28th of October 2016, ConceptoMed and AB Euroform MediPharm entered into an agreement for high-volume capacity manufacturing for Luer-Jack. Euroform MediPharm is a ISO 13485 certified long-term partner within development and production of polymer products for world class customers in Pharmaceutical and Medical Technology industries.
ConceptoMed is proud to announce that it successfully passed the ISO 13485 quality assurance audit, and was issued the international ISO 13485 certificate by SP, our Notified Body.
On the 31st of August 2016, the European Patent Office issued an official document granting the European patent for Luer-Jack. IP Australia, the Australian Government agency that administers intellectual property (IP) rights and legislation relating to patents, issued an official document granting the Australian patent for Luer-Jack - also on the 31st of August 2016.
ConceptoMed proudly announce being named in the Disrupt 100 - a bi-annual Tällt Ventures publication celebrating the businesses with the most potential to influence, change or create new global markets. ConceptoMed were selected from over 1 million global startups and corporate ventures and judged by a selection of global brands.
On the 10th of May 2016, the United States Patent and Trademark office issued an official document granting the US patent for Luer-Jack. The US Luer-Jack patent is an important part of the families of similar filed applications in all important markets world wide, and is a fundamental member of the Luer-Jack patent family.
The UK Intellectual Property Office granted 2nd of March 2016 the UK patent for Luer-Jack Lock. The patent is the frontrunner for similar filed applications (pending) in all important markets world wide and is a fundamental member of the Luer-Jack patent family, ensuring a very simple one-hand operated release of connections for different fluid transfer applications.
The Board of Directors of ConceptoMed AS announce the final completion of the successful private placement of equity in ConceptoMed AS for the period January-February 2016. The placement round was oversubscribed.
Wednesday 27th of January 2016, the Major Norwegian Business Newspaper "Dagens Næringsliv" featured Luer-Jack alongside with strong recommendations from the clinical side in a two-page article.
The Board of Directors of ConceptoMed AS announce the private placement of equity in ConceptoMed AS. Following the share issue, the number of Shareholders in the company amounts to 73 (previously 37). Gross proceeds from the private placement amounts to NOK 89.056.000 (approx. 9,4 MEUR), whereof 25,5 MNOK were subscribed by existing shareholders.
Since April 2012, Dehns has drafted and filed over 50 patent applications across 8 families, as well as a number of design registrations and trade marks. Patents have so far been granted in 4 families, and applications are pending in a number of territories including UK & Europe, PCT, USA, Brazil, Argentina, Australia, China, Hong Kong, India, South Korea, Singapore, Japan, Mexico, and Russia.
LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark) FIRST ORDERS OF LUER-JACK SHIPPING AFTER CE-MARK APPROVAL ConceptoMed today announced that the company has received CE Mark approval for the Luer-Jack® syringe, a new and innovative medical syringe. Luer-Jack® is now ready for the European market and other large markets, where the CE mark allows for market entry.
From June 2014 to July 2015, The Norwegian Research Council (VRI) supported an evaluation research study on Luer-Jack®, a new medical syringe with one-hand disconnection from needles/cannulas and luer type connections. The Intervention Centre of Oslo University Hospital has conducted the study, and the final report was submitted to ConceptoMed today, 1st of September 2015.
ConceptoMed today hosted a very interesting and pleasant meeting with the Prime Minister of Norway, Erna Solberg We raised the question: With the healthcare worker's safety and patient safety in mind; do today's available disposable syringes and connectors fully enable healthcare providers to minimise occurrence of needlestick injuries and hospital acquired blood-borne infections?
When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.
To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.
Please note that our Terms of Use apply to all use of our services.
You can withdraw your consent at any time by unsubscribing or deleting your account.
Email sent to __email__. Click the link there to follow ConceptoMed.
